Sanofi to pay $2.9B for Provention Bio and its diabetes-delaying drug Tzield

Sanofi and Provention have made a $2.9 billion deal for the French drugmaker to acquire the biotech, which last year won approval for its drug to delay the onset of type 1 diabetes.

Sanofi will pay $25 a share, the companies announced in a press release,...

Click to view original post